Our experience in the treatment of botulism
Abstract
Introduction. Botulism is a neuro -intoxication caused by a toxin secreted by Clostridium botulinum. Due to extremely high toxicity and lethality, this toxin can be used as an agent in a biological warfare. Case report. We presented six patients, mean age 28.8 years, who ate canned food and in whom the diagnosis of disease was made based on the typical clinical picture. Predominant symptoms were blurred vision, double vision (diplopia), dry mouth and constipation which were present in all patients. The patient whose disease was recognized only after 23 days and who did not receive the anti botulinum serum underwent the longest hospital treatment. All the patients received antibiotics and 4 patients received antitoxin. Neostigmine and enemas were used for the treatment of the disorder of intestinal motility and constipation. Conclusion. The diagnosis of botulinum was made based on afebrility, preserved states of consciousness, double vision, dry mouth and history data on consumption of suspicious food. Polyvalent serum anti botulinum should be applied as soon as possible because it reduces the occurrence of complications, length of hospital stay and mortality rate.
References
Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol 2004; 44: 167−93.
Konstantinović L, Krstic M, Kostic V, Rankovic J, Jovanovic M, Vrbić M. Clinical infectious diseases. Nis: University of Nis, 2001.(Serbian)
Eriksen T, Brantsaeter AB, Kiehl W, Steffens I. Botulism infection after eating fish in Norway and Germany: two outbreak re-ports. Euro Surveill 2004; 8(3): pii=2366.
Mayo Clinic Staff. Botulism treatments and drugs. Available from: http://www.mayoclinic.org/diseases-conditions/botulism/basics/treatment/con-20025875 [last ac-cesed 2015 September 1].
Rummel A, Eichner T, Weil T, Karnath T, Gutcaits A, Mahrhold S, et al. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc Natl Acad Sci U S A 2007; 104(1): 359−64.
Dong M, Tepp WH, Liu H, Johnson, EA, Chapman ER. Mecha-nism of botulinum neurotoxin B and G entry into hippocam-pal neurons. J Cell Biol 2007; 179(7): 1511−22.
Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM Jr. Biological warfare. A historical perspective. JAMA 1997; 278(5): 412−7.
Ongrade J. Microbial warfare and bioterrorism Orv Hetil 2002; 143(33): 1935−9. (Hungarian)
Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, di-agnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep 2007; 1(2): 122−34.
Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. Public health assessment of potential biological terrorism agents. Emerg Infect Dis 2002; 8(2): 225−30.
Centers for Disease Control and Prevention (CDC). Botulism. General information. Atlanta, Georgia: US Department of Health and Human Services, CDC; 2014.
Sobel J, Tucker N, Sulka A, McLaughlin J, Maslanka S. Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis 2004; 10(9): 1606−11.
Leclair D, Fung J, Isaac-Renton JL, Proulx JF, May-Hadford J, Ellis A, et al. Foodborne botulism in Canada, 1985-2005. Emerg Infect Dis 2013; 19 (6): 961−8.
Bouvet P, Ruimy R, Bouchier C, Faucher N, Mazuet C, Popoff MR. An atypical Clostridium strain related to the Clostridium botu-linum group III strain isolated from a human blood culture. J Clin Microbiol 2014; 52(1): 339−43.
Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, et al. Botulinum toxin as a biological weapon: med-ical and public-health management. JAMA 2001; 285(8): 1059−70.
Marcus N, Hourvitz A. Botulism disease. Harefuah 2002; 141(Spec No): 73−7, 120. (Hebrew)
Gutzwiller FS, Steffen R, Mathys P, Walser S, Schmid H, Mütsch M. Botulism: prevention, clinical diagnostics, therapy and possible threat. Dtsch Med Wochenschr 2008; 133(16): 840−5. (Ger-man)
Arora A, Sharma CM, Kumawat B, Khandelwal D. Rare presenta-tion of botulism with generalized fasciculations. Int J Appl Basic Med Res 2014; 4(1): 56−8.
Angulo FJ, Getz J, Taylor JP, Hendricks KA, Hatheway CL, Barth SS et al. A Large Outbreak of Botulism: The Hazardous Baked Potato. J Infect Dis 1998; 178(1): 172–7.
Sobel J. Botulism. Clin Infect Dis 2005; 41(8): 1167−73.
Khakshoor H, Moghaddam AS, Vejdani AH, Armstrong BK, Moshirfar M. Diplopia as the primary presentation of food-borne botulism. Oman J Ophthalmol 2012; 5(2): 109−11.
Vossen MG, Gattringer KB, Wenisch J, Khalifeh N, Koreny M, Spertini V, et al. The First Case(s) of Botulism in Vienna in 21 Years: A Case Report. Case Rep Infect Dis 2012; 2012: 438989.
Kotan D, Aygul R, Ceylan M, Yilikoglu Y. Clinically and electro-physiologically diagnosed botulinum intoxication. BMJ Case Rep 2013; 2013: pii: bcr0120125678.
Goonetilleke A, Harris JB. Clostridial neurotoxins. Neurol Neu-rosurg Psychiatry 2004; 75(Suppl 3): iii35−9.
Lonati D, Locatelli CA, Fenicia L, Anniballi F, Landri P, Giampreti A, et al. Fatal course of foodborne botulism in an eight-month old infant. Pediatr Rep 2011; 3(4): e31.
Lonati D, Locatelli CA, Fenicia L, Anniballi F, Landri P, Giampreti A, et al. Treatment of foodborne botulism in current clinical toxicology: authors' reply. Pediatr Rep 2012; 4(3): e27.
Robinson RF, Nahata MC. Management of botulism. Ann Pharmacother 2003; 37(1): 127−31.
Tacket CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. Eq-uine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 1984; 76(5): 794−8.
Thanongsaksrikul J, Chaicumpa W. Botulinum neurotoxins and botulism: a novel therapeutic approach. Toxins (Basel) 2011; 3(5): 469−88.
Momose Y, Asakura H, Kitamura M, Okada Y, Ueda Y, Hanabara Y, et al. Food-borne botulism in Japan in March 2012. Int J Infect Dis 2014; 24: 20−2.
Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980; 69(4): 567−70.